Discovery of Potent Inhibitors of Cyclin-Dependent Kinases 7?and 9: Design,Synthesis, Structure-Activity Relationship Analysis and Biological Evaluation |
| |
| Authors: | Dr Renjie Chen Dr Ramin Hassankhani Dr Yi Long Dr Sunita K C Basnet Dr Theodosia Teo Yuchao Yang Dr Laychiluh Mekonnen Dr Mingfeng Yu Prof Shudong Wang |
| |
| Affiliation: | Drug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, SA, 5000 Australia |
| |
| Abstract: | Cyclin-dependent kinases (CDKs) 7 and 9 are deregulated in various types of human cancer and are thus viewed as therapeutic targets. Accordingly, small-molecule inhibitors of both CDKs are highly sought-after. Capitalising on our previous discovery of CDKI-73, a potent CDK9 inhibitor, medicinal chemistry optimisation was pursued. A number of N-pyridinylpyrimidin-2-amines were rationally designed, chemically synthesised and biologically assessed. Among them, N-(6-(4-cyclopentylpiperazin-1-yl)pyridin-3-yl)-4-(imidazo1,2-a]pyrimidin-3-yl)pyrimidin-2-amine was found to be one of the most potent inhibitors of CDKs 7 and 9 as well as the most effective anti-proliferative agent towards multiple human cancer cell lines. The cellular mode of action of this compound was investigated in MV4-11 acute myeloid leukaemia cells, revealing that the compound dampened the kinase activity of cellular CDKs 7 and 9, arrested the cell cycle at sub-G1 phase and induced apoptosis. |
| |
| Keywords: | CDK7 CDK9 inhibitors N-pyridinylpyrimidin-2-amines structure-activity relationships |
|
|
